Literature DB >> 7112817

Serum lipid changes after estrogen therapy in prostatic carcinoma.

N V Bulusu, S B Lewis, S Das, W E Clayton.   

Abstract

A study of serum lipid fraction changes in 15 estrogen-treated patients with carcinoma of the prostate is conducted. Estrogen therapy is known to be associated with cardiovascular complications. certain serum lipid fraction changes, particularly elevated low-density lipoprotein (LDL) and decreased high-density lipoprotein (HDL), are known to increase the risk of cardiovascular diseases. In our study, decrease in total cholesterol, increase in triglycerides, decreased LDL, and LDL/HDL ratio in combination with elevated HDL fraction suggest that the lipid changes are not the mediators of above complications.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7112817     DOI: 10.1016/0090-4295(82)90345-4

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  3 in total

1.  Physiological levels of estradiol correlate with lipid / lipoprotein profiles in healthy men.

Authors:  N Shono; Y Higaki; M Mori; M Nishizumi
Journal:  Environ Health Prev Med       Date:  1999-07       Impact factor: 3.674

2.  Effects of estrogen on low density lipoprotein metabolism in males. Short-term and long-term studies during hormonal treatment of prostatic carcinoma.

Authors:  M Eriksson; L Berglund; M Rudling; P Henriksson; B Angelin
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

3.  Malignancy-associated dyslipidemia.

Authors:  Agata Bielecka-Dąbrowa; Simon Hannam; Jacek Rysz; Maciej Banach
Journal:  Open Cardiovasc Med J       Date:  2011-02-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.